Blog
    Regulatory UpdateFor PhysiciansMarch 31, 2026

    FDA peptide compounding status and GLP-1 safety signals

    Review FDA Category 2 status for BPC-157 and TB-500, compounding withdrawals for CJC-1295, and emerging NAION and aspiration signals for GLP-1 receptor agonists.

    Clinical Question

    What is the current regulatory status of commonly compounded peptides, and what emerging safety signals have been identified in recent clinical data and adverse event reporting?

    Evidence Snapshot

    • Regulatory Status: Multiple peptides designated as Category 2 (significant safety risk) as of September 2023.
    • Compounding Restrictions: Peptides like BPC-157, TB-500, and GHK-Cu are ineligible for routine 503A compounding.
    • Safety Signals: Strong signals for gastrointestinal events and emerging signals for NAION and pulmonary aspiration in GLP-1 RAs.
    • Clinical Outcomes: Phase III data for approved and investigational weight loss agents show weight reduction ranging from 14.9% to 24.2%.

    What the Research Shows

    Regulatory and Compounding Status As of March 2026, the FDA has classified several peptides under Category 2 bulk substances. This designation indicates a "significant safety risk," making these substances "ineligible for routine compounding" under Section 503A. Notably, BPC-157 is listed in Category 2 due to "immunogenicity concerns and lack of safety data." TB-500 also carries Category 2 status, with the FDA citing "immunogenicity risk" and a lack of human exposure data.

    Several substances previously nominated for compounding have seen their nominations withdrawn. For instance, AOD-9604, CJC-1295, Ipamorelin, and Selank all had their nominations withdrawn or were removed in September 2024. CJC-1295 was specifically noted for safety issues such as "increased heart rate."

    Thymosin Alpha-1 presents a complex regulatory landscape. While it is "approved in 35+ countries as Zadaxin," it is "NOT FDA-approved." It was moved from Category 2 to being "removed pending advisory review" in September 2024, yet it remains a "substance of concern under interim policy." Clinically, a Phase III trial (NCT02867267) for sepsis resulted in "no mortality reduction."

    Safety Signals and FAERS Data For Semaglutide, FAERS data through 2023 includes 187,757 GLP-1 RA reports. Strong, labeled signals (Section 6) include nausea and vomiting, which are considered "expected" and "dose-dependent." There is a "strong signal" for delayed gastric emptying, which may impact oral medication absorption and presents a "pre-surgical concern."

    Emerging signals for Semaglutide include:

    • NAION (Nonarteritic Anterior Ischemic Optic Neuropathy): 96 cases through December 2024, with a median onset of 186 days. This is under EMA review as of January 2025.
    • Pulmonary Aspiration: Added to the Ozempic label in 2025, noted as a risk during general anesthesia due to delayed gastric emptying.
    • Intestinal Obstruction / Ileus: An emerging signal added to the label postmarketing.

    Clinical Trial Benchmarks In completed Phase III trials, Semaglutide (STEP 1) demonstrated 14.9% weight loss, while Tirzepatide (SURMOUNT-1) reached 22.5%. Retatrutide, currently in Phase III (TRIUMPH-3), showed 24.2% weight loss at 12mg in Phase II. Tesamorelin is currently FDA-approved for HIV lipodystrophy, showing an "18% VAT reduction."

    Mechanism

    The provided data does not contain mechanistic descriptions for these peptides, other than noting that delayed gastric emptying contributes to the risk of pulmonary aspiration for Semaglutide.

    Limitations of the Evidence

    There is a notable "lack of safety data" and "no human exposure data" for several compounded peptides, including BPC-157 and TB-500. For Semaglutide, suicidal ideation is currently "under evaluation," with FDA data currently not supporting a higher risk versus background rates. Many compounding nominations were withdrawn in 2024, limiting the formal review of their safety profiles. Several substances, such as Selank and Semax, are approved in Russia but lack FDA approval or comprehensive US-based clinical trial data in the provided records.

    Clinical Takeaway

    Physicians should note that many peptides frequently used in clinical settings, such as BPC-157 and TB-500, are currently classified by the FDA as Category 2 substances due to immunogenicity concerns and safety risks. While GLP-1 RAs show significant efficacy in weight loss, practitioners must monitor for emerging postmarketing signals, including NAION and perioperative aspiration risks. Current regulatory data suggests a restrictive environment for the routine compounding of non-FDA-approved peptides.

    Sources

    • REGULATORY STATUS RECORDS: IDs 0abdad3c, 68b0b103, c8181049, 96fb1240, 1a160b34, 116a4f32, 856316f2, fe228995, a11f0210, a6e75c1b.
    • FAERS SAFETY SIGNALS: IDs 502f8ab5, 0296a263, d2135902, 4f021484, 3c2b6572, bcece5fd, afc343ed, be753983, 99f7d6d6, 60c7beaa.
    • CLINICAL TRIAL RECORDS: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, STAY Trial, NCT02867267, NCT068211.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1tesamorelin

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.